Epizyme Inc. (NASDAQ:EPZM) and DiaMedica Therapeutics Inc. (NASDAQ:DMAC), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation of the two firms.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Epizyme Inc.	21.70M	54.36	123.63M	-1.74	0.00
DiaMedica Therapeutics Inc.	N/A	87.29	5.73M	-0.78	0.00

Table 1 demonstrates Epizyme Inc. and DiaMedica Therapeutics Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 represents Epizyme Inc. (NASDAQ:EPZM) and DiaMedica Therapeutics Inc. (NASDAQ:DMAC)’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
Epizyme Inc.	-569.72%	-58.8%	-50.6%
DiaMedica Therapeutics Inc.	0.00%	0%	0%

Analyst Recommendations

Epizyme Inc. and DiaMedica Therapeutics Inc. Recommendations and Ratings are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Epizyme Inc.	0	1	6	2.86
DiaMedica Therapeutics Inc.	0	0	0	0.00

$20.17 is Epizyme Inc.’s average target price while its potential upside is 52.57%.

Institutional & Insider Ownership

Roughly 93.4% of Epizyme Inc. shares are held by institutional investors while 13.78% of DiaMedica Therapeutics Inc. are owned by institutional investors. Insiders held roughly 0.2% of Epizyme Inc.’s shares. Comparatively, DiaMedica Therapeutics Inc. has 17.35% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Epizyme Inc.	3.34%	24.17%	65.67%	8.46%	-28.1%	106.01%
DiaMedica Therapeutics Inc.	-7.36%	-12.82%	-32%	-60.47%	-32.97%	16.84%

For the past year Epizyme Inc.’s stock price has bigger growth than DiaMedica Therapeutics Inc.

Summary

On 6 of the 10 factors DiaMedica Therapeutics Inc. beats Epizyme Inc.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. It has collaboration agreements with Celgene Corporation, Celgene RIVOT Ltd., Genentech Inc., Glaxo Group Limited, and US Oncology Research, as well as with Roche Molecular Systems, Inc., Eisai Co. Ltd., and Lymphoma Study Association. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.